Q32 Bio Inc.
No enriched coverage for $QTTB in the last 7 days.
No SEC Form 4 filings for $QTTB in the last 30 days.
See all $QTTB insider activity →Q32 Bio Inc. (QTTB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 qttb-ex99_1.htm EX-99.1 EX-99.1 Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update -- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; additional details from 36-week results and initial find
Q32 Bio Inc. (QTTB) disclosed in a Schedule 13G/A that Opaleye, L.P., Opaleye Management Inc., and James Silverman beneficially own 931,000 shares of its common stock, or 5.49%, based on 16,956,415 shares outstanding as of May 1, 2026. The filing attributes shared voting and dispositive power to the group and includes a beneficial-ownership disclaimer.
Q32 Bio Inc. (QTTB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d150730dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 Q32 BIO INC. 6,027,399 SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE PRE-FUNDED WARRANTS TO PURCHASE UP TO 4,931,506 SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT July 14, 2026 July 14, 2026 Mo
Recent QTTB coverage spans corporate actions, earnings and financial news.
Clinical efficacy and durability signals for bempikibart increase the probability of progressing toward Phase 3 registration, while the July $200M offering funds the runway.
This is a beneficial-ownership disclosure, not an operational or financial update, but it can still affect positioning and sentiment if the holder is accumulating.
The filing discloses a new equity offering structure (firm shares, pre-funded warrants, and an over-allotment option), which can pressure near-term price via dilution risk.
The dilutive financing is the primary new catalyst, likely pressuring near-term valuation until investors model dilution and use of proceeds.
The priced equity raise is dilutive but provides sizable cash for working capital and bempikibart development, likely pressuring near-term valuation while improving funding runway.
alphai scores every news story that mentions QTTB with an AI model for sentiment and relevance, and aggregates insider trades from Q32 Bio Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Q32 Bio Inc. (QTTB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 qttb-ex99_1.htm EX-99.1 EX-99.1 Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update -- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; additional details from 36-week results and initial find
6 min readQ32 Bio Inc. (QTTB) disclosed in a Schedule 13G/A that Opaleye, L.P., Opaleye Management Inc., and James Silverman beneficially own 931,000 shares of its common stock, or 5.49%, based on 16,956,415 shares outstanding as of May 1, 2026. The filing attributes shared voting and dispositive power to the group and includes a beneficial-ownership disclaimer.
2 min readQ32 Bio Inc. (QTTB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d150730dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 Q32 BIO INC. 6,027,399 SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE PRE-FUNDED WARRANTS TO PURCHASE UP TO 4,931,506 SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT July 14, 2026 July 14, 2026 Mo
2 min readQ32 Bio (NASDAQ:QTTB) fell after announcing a $200M offering. It plans to sell 6,027,399 common shares at $18.25 and pre-funded warrants for 4,931,506 shares at $18.2499, with a $0.0001 exercise price. Underwriters may buy 1,643,835 more shares. Net proceeds fund working capital and bempikibart Phase 2 alopecia areata trials. Analysts expect Aug. 5 earnings.
4 min readQ32 Bio Inc. (Nasdaq: QTTB) priced an underwritten public offering of 6,027,399 shares at $18.25 each and pre-funded warrants for 4,931,506 shares at $18.2499 per warrant. Gross proceeds are expected at about $200 million, with a 30-day option for up to 1,643,835 more shares. Net proceeds will fund working capital and bempikibart (ADX-914) development. Closing is expected around July 16, 2026.
2 min readQ32 Bio shares (QTTB) rose 90.72% after the company reported Phase 2a results for bempikibart in severe alopecia areata. The trial met its primary efficacy goal, with patients showing a 35% average reduction in scalp hair loss severity over 36 weeks, and no serious treatment-related adverse events. The stock later fell about 7% after a $200M offering; Oppenheimer raised its price target to $40.
4 min readBiotech gainers highlighted Q32 Bio (QTTB), up 90.7% to $21.38 after positive Phase 2 SIGNAL-AA results for bempikibart in alopecia areata, and it launched a $200M underwritten stock offering. Agenus (AGEN) rose 82.7% to $6.12 on a planned ~$85M private placement for BOT+BAL Phase 3 ROBBIN1. Other movers: ACTU, GALT, AMWL, SI.
7 min readQ32 Bio Inc. (NASDAQ:QTTB) shares rose sharply after BioWorld Clinical reported on its IL-7 antibody in a Phase II study for alopecia, positioning it as potentially effective without the black-box risks associated with JAK inhibitors. The article says QTTB closed July 13 at $21.38, up $10.17 or 90.7%.
1 min readQ32 Bio Inc. (Nasdaq: QTTB) said it has started an underwritten public offering of $200 million of common stock and, for some investors, pre-funded warrants. It may grant underwriters a 30-day option for up to an additional $30 million. Net proceeds will fund working capital and bempikibart (ADX-914) development.
4 min readQ32 Bio (NASDAQ:QTTB) shares fell about 6% after hours after the company proposed a $200M underwritten public offering of common stock and pre-funded warrants. It may add up to $30M via an underwriter option. Net proceeds are for working capital and advancing bempikibart. The stock had risen 90% earlier on 36-week Phase 2a SIGNAL-AA Part B topline results.
4 min read
